Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3.

Slides:

Advertisements

Similar presentations

Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):

Advertisements

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial K. Ranh Voong, MD MPH, Lincy S. Lal, PhD, Deborah.

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system Benjamin W. Fischer-Valuck, MD,

Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer Thomas J. Pugh, MD, Mark F.

A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer Shervin M. Shirvani, MD, Ann.

Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the.

Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center Kristina D. Woodhouse, MD, Wei-Ting.

Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial Daniel A. Hamstra, MD, PhD, Neil Mariados,

Volume 17, Issue 8, Pages (August 2016)

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy William.

Volume 13, Issue 6, Pages (June 2012)

Clinical Trial Results with OROS® Hydromorphone

Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double- Blind Study in Men With Diabetes Mellitus Irwin Goldstein, MD,

Volume 137, Issue 3, Pages e1 (September 2009)

Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity.

Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer Shervin M. Shirvani, MD, Ann.

Insert tables Insert graphs Insert figure

US radiation oncology practice patterns for posttreatment survivor care Bridget F. Koontz, MD, Rashmi Benda, MD, Jennifer De Los Santos, MD, Karen E.

Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the.

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain Richard L. Rauck, MD, Mark S. Wallace,

Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality Research in Radiation Oncology.

Clinical evaluation of interfractional variations for whole breast radiotherapy using 3- dimensional surface imaging Amish P. Shah, PhD, Tomas Dvorak,

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Volume 17, Issue 8, Pages (August 2016)

Brenda G. Clark, PhD, Robert J

Volume 68, Issue 6, Pages (December 2015)

David J. Brenner, Eric J. Hall, Rochelle E. Curtis, Elaine Ron

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer Christina K. Speirs, MD, PhD, Todd.

Safety of differential radiation dosing in lymph node positive necks treated with IMRT Stephen Sozio, MBS, Zorimar Rivera-Núñez, PhD, Omar Mahmoud, MD,

Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer Nancy El-Bared, MD,

US radiation oncology practice patterns for posttreatment survivor care Bridget F. Koontz, MD, Rashmi Benda, MD, Jennifer De Los Santos, MD, Karen E.

Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer Erik Roelofs,

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality.

Volume 13, Issue 6, Pages (June 2012)

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer Hiram A. Gay, Jung Hun Oh, Aditya P.

Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients Mary P. Walker, DDS, PhD, Brian Wichman, MS, An-Lin Cheng, PhD, James.

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Volume 13, Issue 1, Pages (January 2012)

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Christian Stief European Urology Supplements

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer Michael D. Hasselle, MD, Daniel.

Burnout and Resiliency in Canadian Oncology Residents: A Nationwide Resident and Program Director Survey Hannah Dahn, MD, Angela McGibbon, MD, David.

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the.

Safety considerations for IMRT: Executive summary

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis William A. Stokes, MD, Brian.

Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials Jeff A. Sloan, PhD, Daniel J. Sargent, PhD, Paul J. Novotny, MS, Paul A. Decker,

Safety Profile Assessment: An online tool to gauge safety-critical performance in radiation oncology Peter Dunscombe, PhD, Derek Brown, PhD, Holly Donaldson,

Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American.

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Georgios Ntentas, DPhil, Katerina Dedeckova, MD, Michal.

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability Prashant Gabani, MD, Benjamin W.

Radiation recall precipitated by iodinated nonionic contrast

Pain Response Rates After Conventional Radiation Therapy for Bone Metastases in Prospective Nonrandomized Studies: A Systematic Review Tetsuo Saito,

Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas Kripa Guram, BS, Mark Smith,

Hartmut Porst European Urology Supplements

Technical Innovations and Patient Support in Radiation Oncology

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy Jeanette C. Reece,

Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal.

Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal.

Presentation transcript:

Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial Daniel A. Hamstra, MD, PhD, Neil Mariados, MD, John Sylvester, MD, Dhiren Shah, MD, Eric Gross, MD, Richard Hudes, MD, David Beyer, MD, Steven Kurtzman, MD, Jeffrey Bogart, MD, R. Alex Hsi, MD, Michael Kos, MD, Rodney Ellis, MD, Mark Logsdon, MD, Shawn Zimberg, MD, Kevin Forsythe, MD, Hong Zhang, MD, PhD, Edward Soffen, MD, Patrick Francke, MD, Constantine Mantz, MD, Peter Rossi, MD, Theodore DeWeese, MD, Stephanie Daignault-Newton, MS, Benjamin W. Fischer-Valuck, MD, Anupama Chundury, MD, Hiram A. Gay, MD, Walter Bosch, DSc, Jeff Michalski, MD, MBA Practical Radiation Oncology Volume 8, Issue 1, Pages e7-e15 (January 2018) DOI: 10.1016/j.prro.2017.07.008 Copyright © 2017 The Authors Terms and Conditions

Figure 1 (A) Penile bulb dose in 5-Gy increments (5-80 Gy). Dose bins indicated with an asterisk (*) were statistically different (P < .05). (B) The proportion of patients by treatment arm achieving the dose constraints recommended based upon the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer trial (goals are indicated in parentheses). Practical Radiation Oncology 2018 8, e7-e15DOI: (10.1016/j.prro.2017.07.008) Copyright © 2017 The Authors Terms and Conditions

Figure 2 (A) Erections firm enough for intercourse at 15 months as a function of penile bulb dose broken down by tertiles. (B) Erectile function assessed by the dose constraints recommended based upon the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer trial. (C) Erectile function over time by V50 and mean dose. *P < .05. Dmax, maximum dose; RT, radiation therapy; V50, percentage of penile bulb receiving doses ≥50 Gy. Practical Radiation Oncology 2018 8, e7-e15DOI: (10.1016/j.prro.2017.07.008) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Expanded Prostate Cancer Index Composite (EPIC) sexual summary score over time (and standard deviation) as a function of treatment arm for those with better sexual quality of life (EPIC >60) at baseline (A) or for those with moderate-severe sexual dysfunction (EPIC ≤60) at baseline (B). Practical Radiation Oncology 2018 8, e7-e15DOI: (10.1016/j.prro.2017.07.008) Copyright © 2017 The Authors Terms and Conditions

Figure 4 For men with better baseline sexual function (EPIC >60), the percentage of patients over time by treatment arm having a decline in sexual function meeting threshold for MID (11 points) (A) or 2× MID (22 points) (B). ED, erectile dysfunction; QOL, quality of life; MID, minimal clinically important difference. See Fig 3 for other abbreviations. Practical Radiation Oncology 2018 8, e7-e15DOI: (10.1016/j.prro.2017.07.008) Copyright © 2017 The Authors Terms and Conditions

Figure 5 (A) Erections firm enough for intercourse as a function of treatment arm for men with EPIC >60, who had erections sufficient for intercourse at baseline, and responded at baseline and 3 years. (B) The difference in the percentage of men with good baseline function reporting “moderate” to “severe” problems for each of the EPIC sexual domain items between baseline and 3 years as a function of treatment arm. *P < .05. Abbreviation as in Fig 3. Practical Radiation Oncology 2018 8, e7-e15DOI: (10.1016/j.prro.2017.07.008) Copyright © 2017 The Authors Terms and Conditions